Sotera Health falls after third-quarter results that beat EPS but flagged softer device demand

What happened

Sotera Health (SHC) fell 9.6% on November 3, 2026, after reporting third-quarter results that beat EPS estimates but noted softer medical-device demand in Europe and left full-year net revenue guidance intact. The company said third-quarter net revenues were up 4.4% both on an as-reported basis and on a constant currency basis, and Adjusted EBITDA increased 3.9%. Management reaffirmed the full-year 2026 net revenue growth outlook of 5.25%–6.75% while flagging continued weakness from medical-device customers in Europe late in the quarter.

How big was the move

The stock closed at $16.03, a day change that was 5.1 times a typical daily move for this stock and 10.3 percentage points worse than the healthcare sector median on the day. Trading volume was 2.5 times its 20-day average, and the S&P 500 rose 0.4% on the same day. Over the last five sessions the stock fell 13.3% while the S&P 500 over five sessions fell 2.0%.

The technical picture

The stock was 10.8% below its 20-day moving average and 13.0% below its 50-day moving average, while 5.6% below its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, but the Relative Strength Index (14 days) at 27 is below 30, a level often called oversold. The shares are 19.2% below the 52-week high and have fallen 13.6% over one month and 10.8% over three months.

Fundamentals and valuation

For the four quarters through September 30, 2026, net revenue was $1.23 billion, which grew 6.9% from a year earlier, and diluted earnings per share were $0.60, which rose 209.6% from a year earlier. Gross margin was 54.4% versus 56.0% a year earlier, while operating margin widened to 36.0% from 29.9% a year earlier. Free-cash-flow margin was 11.0% and return on invested capital was 8.8%. The balance sheet showed net debt of 3.4 times EBITDA and share count over one year increased by 0.9%.

Valuation measures painted a mixed picture for investors weighing near-term weakness against longer-term gains. The stock traded at 26.6 times trailing earnings and 16.3 times expected forward earnings, with a free-cash-flow yield of 2.6%. Its price-to-earnings ratio is lower than 88% of its own readings over the past five years, whose five-year median is 61.1 times earnings. PromtFinance scores rank the company strong on Value at 83 and strong on Revisions at 85, with Growth 66 and Quality 78.

Earnings and analyst expectations

Sotera Health reported on November 3, 2026, Adjusted EPS of $0.29 against $0.27 expected, 7.9% above estimates, marking seven consecutive quarters beating estimates and an average surprise over the last four reports of 7.7% above estimates. The company posted Q3 2026 net income of $58 million and GAAP diluted EPS of $0.20, with Adjusted EBITDA increasing 3.9% (4.0% on a constant currency basis).

Analysts remained broadly positive after the report. The consensus rating is Buy, with 92% of analysts assigning a Share rating of Buy or Strong Buy across 12 analysts. The consensus price target is $21.33, 33.1% above the closing price on November 3, 2026. Typical two-day reactions after recent reports have been modestly positive, with a rise of 1.2% after recent releases.

Investors focused on the regional softness that management highlighted. The company said weaker demand from medical-device customers in Europe weighed on volumes late in the quarter and that the softness carried into the fourth quarter. Because management kept the full-year net revenue growth outlook unchanged, attention centered on how quickly volumes in that region might recover and what that implied for fourth-quarter momentum.

What to watch

• February 23, 2027: next scheduled earnings report
• Management reaffirmed full-year 2026 net revenue growth outlook of 5.25%–6.75% on November 3, 2026
• In the past five years the stock had 9 sessions with a decline of at least 9.6%; twenty trading days later the median result was a decline of 9.6%, and 1 of 9 were higher
• Consensus price target $21.33, 33.1% above the closing price on November 3, 2026
• Share count over one year increased by 0.9%